# Ginkgo Bioworks Holdings, Inc.: financial statements, quarterly

DNA · NYSE · CIK 1830214 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dna.md) · [Financials](/companies/dna/financials.md) · [Filings](/companies/dna/filings.md) · [Insiders](/companies/dna/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dna/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [55.4](/filings/0001628280-24-047284.md) | [34.8 d](/filings/0001628280-26-012346.md) | [37.9](/filings/0001628280-25-022761.md) | [56.2](/filings/0001628280-25-038982.md) | [89.0](/filings/0001628280-25-050193.md) | [43.8 d](/filings/0001628280-26-012346.md) | [38.2](/filings/0001628280-26-032116.md) | [39.1](/filings/0001628280-26-054298.md) | [38.8](/filings/0001628280-25-050193.md) | [33.4 d](/filings/0001628280-26-012346.md) | [19.5](/filings/0001628280-26-032116.md) | [20.2](/filings/0001628280-26-054298.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [4.1](/filings/0001628280-26-032116.md) | [5.4](/filings/0001628280-26-054298.md) | not reported | not reported | [3.1](/filings/0001628280-26-032116.md) | [1.7](/filings/0001628280-26-054298.md) |
| Research and development | $m | [157](/filings/0001628280-24-047284.md) | [117 d](/filings/0001628280-26-012346.md) | [136](/filings/0001628280-25-022761.md) | [134](/filings/0001628280-25-038982.md) | [77.0](/filings/0001628280-25-050193.md) | [76.4 d](/filings/0001628280-26-012346.md) | [70.9](/filings/0001628280-26-032116.md) | [53.4](/filings/0001628280-26-054298.md) | [69.4](/filings/0001628280-25-050193.md) | [50.1 d](/filings/0001628280-26-012346.md) | [49.9](/filings/0001628280-26-032116.md) | [46.2](/filings/0001628280-26-054298.md) |
| Operating income | $m | [(286)](/filings/0001628280-24-047284.md) | [(178) d](/filings/0001628280-26-012346.md) | [(178)](/filings/0001628280-25-022761.md) | [(223)](/filings/0001628280-25-038982.md) | [(55.2)](/filings/0001628280-25-050193.md) | [(104) d](/filings/0001628280-26-012346.md) | [(81.0)](/filings/0001628280-26-032116.md) | [(58.2)](/filings/0001628280-26-054298.md) | [(90.0)](/filings/0001628280-25-050193.md) | [(70.8) d](/filings/0001628280-26-012346.md) | [(71.4)](/filings/0001628280-26-032116.md) | [(58.5)](/filings/0001628280-26-054298.md) |
| Interest expense | $m | [(15.0)](/filings/0001628280-24-047284.md) | [44.0 d](/filings/0001628280-24-008052.md) | not reported | [(10.3)](/filings/0001628280-24-036231.md) | [(9.3)](/filings/0001628280-24-047284.md) | [31.4 d](/filings/0001628280-26-012346.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.0)](/filings/0001628280-24-047284.md) | [(0.2) d](/filings/0001628280-26-012346.md) | [0.0](/filings/0001628280-25-022761.md) | [0.2](/filings/0001628280-25-038982.md) | [(0.4)](/filings/0001628280-25-050193.md) | [(0.3) d](/filings/0001628280-26-012346.md) | [0.1](/filings/0001628280-26-032116.md) | [(0.3)](/filings/0001628280-26-054298.md) | [0.0](/filings/0001628280-25-050193.md) | [(0.6) d](/filings/0001628280-26-012346.md) | [(0.1)](/filings/0001628280-26-032116.md) | [0.1](/filings/0001628280-26-054298.md) |
| Net income | $m | [(303)](/filings/0001628280-24-047284.md) | [(212) d](/filings/0001628280-26-012346.md) | [(166)](/filings/0001628280-25-022761.md) | [(217)](/filings/0001628280-24-036231.md) | [(56.4)](/filings/0001628280-25-050193.md) | [(108) d](/filings/0001628280-26-012346.md) | [(91.0)](/filings/0001628280-26-032116.md) | [(60.3)](/filings/0001628280-26-054298.md) | [(80.8)](/filings/0001628280-25-050193.md) | [(80.8) d](/filings/0001628280-26-012346.md) | [(82.6)](/filings/0001628280-26-032116.md) | [(46.7)](/filings/0001628280-26-054298.md) |
| Diluted EPS | $ per share | [(6.21)](/filings/0001628280-24-047284.md) | not reported | [(3.32)](/filings/0001628280-25-022761.md) | [(4.23)](/filings/0001628280-25-038982.md) | [(1.08)](/filings/0001628280-25-050193.md) | not reported | [(1.68)](/filings/0001628280-25-022761.md) | [(1.10)](/filings/0001628280-25-038982.md) | [(1.45)](/filings/0001628280-25-050193.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | [(6.21)](/filings/0001628280-24-047284.md) | not reported | [(3.31)](/filings/0001628280-25-022761.md) | [(4.23)](/filings/0001628280-25-038982.md) | [(1.08)](/filings/0001628280-25-050193.md) | not reported | [(1.68)](/filings/0001628280-26-032116.md) | [(1.10)](/filings/0001628280-26-054298.md) | [(1.45)](/filings/0001628280-25-050193.md) | not reported | [(1.39)](/filings/0001628280-26-032116.md) | [(0.75)](/filings/0001628280-26-054298.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1,049](/filings/0001628280-24-047284.md) | [944](/filings/0001628280-26-012346.md) | [840](/filings/0001628280-25-022761.md) | [730](/filings/0001628280-25-038982.md) | [616](/filings/0001628280-25-050193.md) | [562](/filings/0001628280-26-054298.md) | [312](/filings/0001628280-26-032116.md) | [204](/filings/0001628280-26-054298.md) | [111](/filings/0001628280-25-050193.md) | [167](/filings/0001628280-26-054298.md) | [144](/filings/0001628280-26-032116.md) | [84.5](/filings/0001628280-26-054298.md) |
| Current assets | $m | [1,142](/filings/0001628280-23-037927.md) | [1,002](/filings/0001628280-25-007819.md) | [903](/filings/0001628280-24-022229.md) | [783](/filings/0001628280-24-036231.md) | [662](/filings/0001628280-24-047284.md) | [603](/filings/0001628280-26-012346.md) | [565](/filings/0001628280-25-022761.md) | [523](/filings/0001628280-25-038982.md) | [506](/filings/0001628280-25-050193.md) | [472](/filings/0001628280-26-054298.md) | [410](/filings/0001628280-26-032116.md) | [333](/filings/0001628280-26-054298.md) |
| Total assets | $m | [2,026](/filings/0001628280-23-037927.md) | [1,665](/filings/0001628280-25-007819.md) | [1,582](/filings/0001628280-24-022229.md) | [1,625](/filings/0001628280-24-036231.md) | [1,481](/filings/0001628280-24-047284.md) | [1,377](/filings/0001628280-26-012346.md) | [1,293](/filings/0001628280-25-022761.md) | [1,231](/filings/0001628280-25-038982.md) | [1,189](/filings/0001628280-25-050193.md) | [1,120](/filings/0001628280-26-054298.md) | [1,033](/filings/0001628280-26-032116.md) | [990](/filings/0001628280-26-054298.md) |
| Current liabilities | $m | [168](/filings/0001628280-23-037927.md) | [164](/filings/0001628280-25-007819.md) | [169](/filings/0001628280-24-022229.md) | [166](/filings/0001628280-24-036231.md) | [114](/filings/0001628280-24-047284.md) | [107](/filings/0001628280-26-012346.md) | [116](/filings/0001628280-25-022761.md) | [96.7](/filings/0001628280-25-038982.md) | [115](/filings/0001628280-25-050193.md) | [96.0](/filings/0001628280-26-054298.md) | [79.6](/filings/0001628280-26-032116.md) | [72.7](/filings/0001628280-26-054298.md) |
| Total liabilities | $m | [774](/filings/0001628280-23-037927.md) | [568](/filings/0001628280-25-007819.md) | [594](/filings/0001628280-24-022229.md) | [792](/filings/0001628280-24-036231.md) | [683](/filings/0001628280-24-047284.md) | [661](/filings/0001628280-26-012346.md) | [646](/filings/0001628280-25-022761.md) | [618](/filings/0001628280-25-038982.md) | [629](/filings/0001628280-25-050193.md) | [611](/filings/0001628280-26-054298.md) | [590](/filings/0001628280-26-032116.md) | [570](/filings/0001628280-26-054298.md) |
| Shareholders' equity | $m | [1,253](/filings/0001628280-24-047284.md) | [1,097](/filings/0001628280-26-012346.md) | [987](/filings/0001628280-25-038982.md) | [833](/filings/0001628280-25-050193.md) | [798](/filings/0001628280-25-050193.md) | [716](/filings/0001628280-26-054298.md) | [647](/filings/0001628280-26-054298.md) | [613](/filings/0001628280-26-054298.md) | [560](/filings/0001628280-25-050193.md) | [509](/filings/0001628280-26-054298.md) | [443](/filings/0001628280-26-054298.md) | [420](/filings/0001628280-26-054298.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(73.6) d](/filings/0001628280-24-047284.md) | [(57.8) d](/filings/0001628280-26-012346.md) | [(89.3)](/filings/0001628280-25-022761.md) | [(84.4) d](/filings/0001628280-25-038982.md) | [(104) d](/filings/0001628280-25-050193.md) | [(42.4) d](/filings/0001628280-26-012346.md) | [(51.5)](/filings/0001628280-26-032116.md) | [(40.3) d](/filings/0001628280-26-054298.md) | [(31.6) d](/filings/0001628280-25-050193.md) | [(47.7) d](/filings/0001628280-26-012346.md) | [(46.7)](/filings/0001628280-26-032116.md) | [(44.3) d](/filings/0001628280-26-054298.md) |
| Capital expenditure | $m | [4.4 d](/filings/0001628280-24-047284.md) | [3.4 d](/filings/0001628280-26-012346.md) | [6.7](/filings/0001628280-25-022761.md) | [27.0 d](/filings/0001628280-25-038982.md) | [15.1 d](/filings/0001628280-25-050193.md) | [13.7 d](/filings/0001628280-26-012346.md) | [7.6](/filings/0001628280-26-032116.md) | [0.0 d](/filings/0001628280-26-054298.md) | [0.0 d](/filings/0001628280-25-050193.md) | [0.0 d](/filings/0001628280-26-012346.md) | [1.9](/filings/0001628280-26-032116.md) | [2.6 d](/filings/0001628280-26-054298.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.6](/filings/0000950170-23-020535.md) | [1,621](/filings/0000950170-23-040721.md) | [1,631](/filings/0001628280-23-037927.md) | [1,917](/filings/0001628280-24-022229.md) | [1,933](/filings/0001628280-24-036231.md) | [48.8](/filings/0001628280-24-047284.md) | [50.1](/filings/0001628280-25-022761.md) | [51.4](/filings/0001628280-25-038982.md) | [52.2](/filings/0001628280-25-050193.md) | [54.2](/filings/0001628280-25-022761.md) | [54.9](/filings/0001628280-25-038982.md) | [55.6](/filings/0001628280-25-050193.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.